Background {#Sec1}
==========

Colorectal cancer (CRC) is one of the major leading causes of cancer-related deaths in the world \[[@CR1]\]. Although the overall survival of CRC patients has improved, the prognosis of patients with metastasis or recurrence is still relatively poor \[[@CR2]\]. Angiogenesis is one of the major hallmarks of cancer \[[@CR3]\], facilitating tumor development, progression and metastasis \[[@CR4], [@CR5]\]. Thus, understanding the molecular mechanism and identifying of novel molecular biomarker in angiogenesis could benefit clinical management of CRC patients.

Granulin epithelin precursor (GEP), also known as progranulin, acrogranin, proepithelin, and GP88/PC-cell derived growth factor, is a secreted glycoprotein composed of 7.5 repeats of cysteine-rich motif \[[@CR6], [@CR7]\]. Physiologically, it is expressed in immune cells \[[@CR8], [@CR9]\], neurons \[[@CR10]\], epithelial cells \[[@CR11]\] and chondrocytes \[[@CR12]\], mediating wound healing, neurodegeneration and cartilage development \[[@CR7], [@CR10]--[@CR12]\]. Pathologically, high expression levels of GEP are associated with poor prognosis in hepatocellular carcinoma, ovarian cancer \[[@CR13]\], bladder cancer \[[@CR14]\] and glioblastoma \[[@CR15]\]. Functional studies reveals GEP acts as a growth factor to stimulate proliferation and migration, and confer chemoresistance in many types of cancers including breast cancer \[[@CR16], [@CR17]\], ovarian cancer \[[@CR18], [@CR19]\], liver cancer \[[@CR20], [@CR21]\] and bile duct cancer \[[@CR22]\].

As the expression and functional role of GEP in CRC is unclear. In this study, the clinical significance and the function of GEP in CRC will be comprehensively revealed.

Methods {#Sec2}
=======

Patients and specimens {#Sec3}
----------------------

Between 1999 and 2013, 190 patients undergoing resection of primary CRCs at Prince of Wales Hospital, the Chinese University of Hong Kong were recruited in the present study. None of the patients received any neo-adjuvant therapy. The age of the patients ranged from 34 to 92 years, with a median age of 67.4 years. There were 106 men and 84 women. Tumors were staged according to the pathological tumor-node-metastasis (pTNM) staging system, 7th version. Distribution of the pTNM stages and other clinicopathological features is listed in Table [1](#Tab1){ref-type="table"}. The patients were regularly followed up according to the institutional practice. Disease free survival was defined as the period from the date of curative surgery of primary tumor to the date that the patient survived without any signs or symptoms of that cancer. Overall survival was defined as the period from the date of curative surgery of primary tumor to the date of cancer-related death or last follow-up. The last update of the database 31 December 2015. The study was approved by Committees for Clinical Research Ethics of Joint Chinese University of Hong Kong-New Territories East Cluster.Table 1Clinicopathologic correlation of GEP expression in colorectal cancer (n = 190, significant *P*-value in italic format)GEP expression (n = 190)*P*-valueAllH-score ≥ 150H-score \< 15098 (51.6%)92 (48.4%)Male gender106 (55.8%)51 (52.0%)55 (59.8%)0.283Age at operation (years, mean ± SD)67.4 ± 12.166.7 ± 12.668.2 ± 11.60.386Location*0.032* Right colon51 (26.8%)27 (29.0%)24 (26.4%) Left colon36 (18.9%)23 (24.7%)13 (14.3%) Rectum88 (46.3%)36 (38.7%)52 (57.1%) Synchronous9 (4.7%)7 (7.5%)2 (2.2%) Unknown6 (3.2%)//Size (cm, mean ± SD)4.5 ± 1.74.6 ± 1.94.3 ± 1.60.257Differentiation Well2 (1.1%)02 (2.2%)0.052 Moderate180 (94.7%)92 (95.8%)88 (97.8%) Poor4 (2.1%)4 (4.2%)0 Others4 (2.1%)//AJCC stage\< *0.01* I17 (8.9%)5 (5.1%)12 (13.0%) II57 (30.0%)19 (19.4%)38 (41.3%) III56 (29.5%)27 (27.6%)29 (31.5%) IV60 (31.6%)47 (48.0%)13 (14.1%)T stage0.583 T15 (2.6%)3 (3.1%)2 (2.2%) T219 (10.0%)8 (8.2%)11 (12.0%) T3122 (64.2%)61 (62.2%)61 (66.3%) T444 (23.2%)26 (26.5%)18 (19.8%)N stage\< *0.01* N089 (46.8%)35 (35.7%)54 (58.7%) N161 (32.1%)34 (34.7%)27 (29.3%) N240 (21.1%)29 (29.6%)11 (12.0%)M stage\< *0.01* M0129 (67.9%)50 (51.0%)79 (85.9%) M161 (32.1%)48 (49.0%)13 (14.1%)Pre-ops CEA (ng/ml, mean ± SD)142.0 ± 838.4218.9 ± 1118.153.4 ± 256.50.194

Cell lines and cell culture {#Sec4}
---------------------------

Human CRC cell lines Caco2, DLD-1, HCT 116, HT-29, LoVo, LS 180, SW480 and SW620 were all obtained American Type Culture Collection (ATCC, Manassas, VA, USA). All cell lines were cultured in media according to manufacturer's instructions.

For transient transfection, DLD-1 or HCT 116 cells were transfected using lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA, USA) by siGEP or siRNA control (Qiagen, Hilden, Germany) to interfere GEP expression. Procedures of transfection were performed according to the manufacturer's instructions. Cells stably expressing downregulated GEP mediated by shRNA was established using retrovirus system. The shRNA information for GEP knockdown can be found in Additional file [1](#MOESM1){ref-type="media"}.

Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) {#Sec5}
----------------------------------------------------------------------

Total RNA from cells was extracted by Trizol (Thermo Fisher Scientific) according to the manufacturer's instruction. cDNAs were synthesized using High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific) as protocol. Quantification was performed with the ABI 7500 Real Time PCR system (Applied Biosystems, Foster City, CA, USA). Primers and probes for GEP were GEP-forward (5′-CAA ATG GCC CAC AAC ACT GA-3′), GEP-reverse (5′-CCC TGA GAC GGT AAA GAT GCA-3′) and GEP-probe (5′-6FAM CCA CTG CTC TGC CGG CCA CTC MGBNFQ-3′). Primer and probe reagents for control 18s were ready-made reagents (Pre-Developed TaqMan Assay Reagents, Applied Biosystems). All experiments were performed in a minimum of three replicates.

Immunohistochemistry (IHC) {#Sec6}
--------------------------

Immunohistochemistry was performed on 5 µm sections cut from tissue microarray blocks using Dako Envision Plus System (Dako, Carpinteria, CA, USA) following the manufacturer's instruction with modifications. Briefly, antigen retrieval was followed by endogenous peroxidase blocking and the following antibody in accordance with the manufacturer's recommendations: GEP \[[@CR23]\] (Clone: A23, 1:800). The cytoplasmic expression of was assessed by using histoscore (H-score) \[[@CR24]\] for the staining intensity and the actual percentage of stained cells in the cytoplasm by two of the investigators. The H-score was obtained by the formula: 3 × percentage of strongly staining + 2 × percentage of moderately staining + percentage of weakly staining, giving a range of 0--300. The staining was considered positive when there was moderate or strong immunoreactivity over the cutoff point above 150.

Western blot analysis {#Sec7}
---------------------

Equal total protein was separated by SDS-PAGE and transferred to nitrocellulose membrane. GEP was detected with a monoclonal anti-GEP antibody (1:5000 dilution). Other primary antibodies were from Cell Signaling (Danvers, MA, USA) commercially including Cyclin D1 (1:1000, \#2926), cleaved PARP (Asp214) (1:1000, \#9541), phospho-MAPK/ERK (1:2000, \#9106), MAPK/ERK (1:1000, \#9102), Caspase-8 (1:1000, \#9746), Cleaved Caspase-8 (1:1000, \#9748), Caspase-3 (1:1000, \#9662), Cleaved Caspase-3 (1:1000, \#9661). The secondary antibodies were anti-Mouse IgG-HRP (1:15,000, 00049039, Dako, Denmark) and anti-Rabbit IgG-HRP (1:5000, 00028856, Dako). The western blot bands were quantified by ImageJ.

Cell proliferation assay {#Sec8}
------------------------

Cell proliferation assays were performed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-trazolium bromide (MTT, Sigma-Aldrich, St. Louis, MO, USA) assay following the manufactures' protocol. Briefly, CRC cells which have been transfected with siGEP or siControl were plated in 96-well plate. Cell viability was measured at 24, 48, 72, 96, and 120 h. Finally, the optical density was determined at 570 and 690 nm wavelength light absorption (Victor3, Perken Elmer, MA, USA).

Monolayer colony formation assay {#Sec9}
--------------------------------

Anchorage-dependent growth was assessed by monolayer colony formation. 6-well plates were used at a density of 1 × 10^3^ to 5 × 10^3^ for transfected cells. Cells were incubated at 37 °C for 14--21 days until colonies can obviously be observed. Colonies were fixed with methanol for 5 min and stained with 0.5% crystal violet. Colonies with cell numbers of more than 50 cells per colony were counted. The experiments were performed in duplicate wells in three independent experiments.

Invasion and migration assay {#Sec10}
----------------------------

Cell invasion or migration activity were performed using 24 well biocoat matrigel invasion chambers or sterilized transwell insert chambers (Corning, Bedford, MA, USA). Cells were harvested after transfected with siGEP or siControl for 24 h and re-plated with serum free medium in the upper chamber. The lower chamber was filled with culture medium containing 10% FBS as the chemoattractant. After 48 h, the cells that moved to the lower surface of polycarbonate membrane were stained with 0.5% crystal violet and counted at five random 200× fields.

In vivo tumorigenic assays {#Sec11}
--------------------------

1 × 10^6^ transfected CRC cells in 100 μl PBS were injected subcutaneously into the dorsal region of anaesthetized nude mice (5 mice/construct, control in left and treatment in right). When tumor was formed, tumor diameter was measured and documented every 3 days for 3 weeks. At the end of investigation, mice were sacrificed, and xenografts were collected for diameter check and weigh valuation. The animal handling and all experimental procedures were approved by the Department of Health of Hong Kong and the Animal Experimentation Ethics Committee, The Chinese University of Hong Kong.

Flow cytometry analysis {#Sec12}
-----------------------

Cells transfected with siGEP or siControl were harvested at 24, 48 or 72 h after transfection. Then live cells were incubated in the mixture of propidium iodide (PI) and annexin V-fluorescein isothiocyanate (Thermo Fisher Scientific) for apoptosis study. Harvested cells were fixed and incubated with PI and RNase A at 4 °C for cell cycle analysis. Finally, cells were determined by FACS Calibur Flow Cytometer (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) and CellQuest program.

Luciferase reporter assay {#Sec13}
-------------------------

The firefly luciferase construct was co-transfected with Renilla luciferase vector (Qiagen) as a control into the siRNA treated cells. Dual Luciferase Reporter Assay System (Promega, Fitchburg, Wisconsin, USA) was employed to check the luciferase activity after 48 h' transfection. The results were expressed as the ratio of firefly luciferase activity to renilla luciferase activity. Experiments were repeated in triplicate.

Statistical analysis {#Sec14}
--------------------

The statistical analysis was performed using IBM SPSS Statistics (Version 19.0, Armonk, NY, USA). The expression level of GEP in paired non-tumor and tumor tissues was compared with paired Student's t-test. Independent Student's t-test was used to compare the mean value of any two groups. The Pearson χ^2^ test was used to analyze the association of target expression with clinicopathological parameters. Survival curves were drawn using the Kaplan--Meier method and compared by means of the log-rank test. Univariable and multivariable Cox proportional hazard regression models were used to analyze independent prognostic factors. *P* \< 0.05 was considered statistically significant. *P* \< 0.01 was considered highly statistically significant.

Results {#Sec15}
=======

GEP is overexpressed in CRC {#Sec16}
---------------------------

GEP mRNA expression was up-regulated in 6/8 CRC cell lines compared with the normal colon epithelium by qRT-PCR (Fig. [1](#Fig1){ref-type="fig"}a). We analyzed GEP expression in cellular datasets available through ONCOMINE (<http://www.oncomine.org/>), an online collection of microarrays. Using the Ki colon dataset \[[@CR7]\], we observed that GEP expression was lower in normal colon compared to colon cancer tissues (Fig. [1](#Fig1){ref-type="fig"}b). Using immunohistochemical staining on 190 CRC and 70 normal colon samples, GEP protein was predominantly localized in the cytoplasm and most of the CRC cases demonstrated abundant GEP protein compared with non-tumorous tissues (Fig. [1](#Fig1){ref-type="fig"}c). High expression (H-score ≥ 150) of GEP protein was detected in 51.6% (98/190) of tumor tissues. Whereas, only 4.3% (3/70) of normal tissues were found high GEP expression (*P *\< 0.01, Fig. [1](#Fig1){ref-type="fig"}d).Fig. 1The expression of GEP in CRC. **a** GEP mRNA expression was significantly higher in CRC cell lines (6/8) than normal colon. **b** GEP mRNA expression was significantly higher in colon cancer tissues than the normal colon in the Ki colon dataset of ONCOMINE. **c** Representative IHC images showing no expression in normal colon (H-score = 0), high expression in tumor cells (H-score \> 150), and low expression in tumor cells (H-score ≤ 150) of GEP in human CRC samples. **d** GEP protein expression was higher in primary CRCs (51.6%), compared to normal colonic mucosa (4.3%). (\**P* \< 0.05; \*\**P* \< 0.01)

High GEP expression correlates with poor survival in CRC patients {#Sec17}
-----------------------------------------------------------------

The correlation of GEP with clinicopathologic parameters in CRC patients was summarized in Table [1](#Tab1){ref-type="table"}. GEP expression varied significantly among CRC samples with different tumor locations (*P* = 0.032), AJCC stages (*P* \< 0.01), lymph node involvement (*P* \< 0.01) and distant metastasis status (*P* \< 0.01). Specifically, a high GEP protein level more frequently occurred in tumors located on colon than that on rectum (*P* \< 0.05, Fig. [2](#Fig2){ref-type="fig"}a). High GEP expression was also more commonly happened in patients with advanced AJCC stage (Stage III/IV, *P* \< 0.01, Fig. [2](#Fig2){ref-type="fig"}b), including the presence of lymphatic (*P* \< 0.01, Fig. [2](#Fig2){ref-type="fig"}c) and distant metastasis (*P* \< 0.01, Table [1](#Tab1){ref-type="table"}).Fig. 2Clinicopathological and prognostic features of CRC patients with high GEP expression. **a** High GEP protein level was more frequently occurred in tumor located on colon than that on rectum (*P* \< 0.05). **b** Higher GEP expression was also more commonly happened in patients with advanced AJCC stage (Stage III/IV, *P* \< 0.01). **c** GEP upregulation was more involved in patients with lymphatic metastasis (*P* \< 0.01). **d**, **e** GEP high expression correlated with both shorter disease-free survival (*P* \< 0.01, **d**) and overall survival (*P* \< 0.01, **e**). (\**P* \< 0.05; \*\**P* \< 0.01)

High GEP expression was associated with shorter disease-free survival and overall survival (*P* \< 0.01, Fig. [2](#Fig2){ref-type="fig"}d, e). Other Clinicopathological parameters such as right-side colon, poor differentiation, tumor invades adjacent organs or perforates the visceral peritoneum (T4), lymph node involvement (N1/2), distant metastasis (M1), and high CEA level before operation (\> 10 ng/ml) also predicted worse disease-free survival and overall survival (Additional file [2](#MOESM2){ref-type="media"}). By multivariable Cox regression, compared with those classic prognostic parameters, high GEP expression was not an independent prognosticator for patients' disease-free (Additional file [3](#MOESM3){ref-type="media"}) and overall survival (Additional file [4](#MOESM4){ref-type="media"}).

GEP exerts an oncogenic function on CRC cells {#Sec18}
---------------------------------------------

In DLD-1 and HCT 116 cell lines with endogenous high GEP expression, siRNA-mediated knockdown reduced GEP expression at mRNA (*P* \< 0.01, Fig. [3](#Fig3){ref-type="fig"}a). siGEP treatments significantly decreased cell proliferation (Fig. [3](#Fig3){ref-type="fig"}b), anchorage-dependent growth (Fig. [3](#Fig3){ref-type="fig"}c), and abilities of the invasion (Fig. [3](#Fig3){ref-type="fig"}d) and migration (Fig. [3](#Fig3){ref-type="fig"}e) in both DLD-1 and HCT 116 cells compared to the control group. These observations suggested that GEP had oncogenic properties.Fig. 3GEP exerts oncogenic function in CRC cells. **a** GEP showed decreased expression at the mRNA level by qRT-PCR in DLD-1 and HCT 116 cells. **b** A significantly decreased proliferation was observed in the siGEP treated group compared with siControl group in all 2 cell lines examined (*P* \< 0.01). **c** GEP knockdown significantly reduced anchorage-dependent growth in CRC cell lines by Foci-Formation assay (*P* \< 0.01). **d**, **e** Knockdown GEP expression by siRNA eliminated the ability of the and invasion (**d**) and migration (**e**) in both DLD-1 and HCT 116 cells compared to the control group. **f** Pictures of tumors isolated from nude mice at the end of investigation (Left); The tumor growth was monitored and calculated in the line chart (Middle) and histogram represented mean of the tumor weight (Right) from the shControl and shGEP groups. (\**P* \< 0.05; \*\**P* \< 0.01)

To determine the anti-tumor effect of shGEP in vivo, DLD-1 cells stably expressing GEP shRNA was established using retrovirus system. shControl and shGEP were subcutaneously injected into the left and right flanks of nude mice respectively. The shGEP group formed smaller tumor within 27 days (Fig. [3](#Fig3){ref-type="fig"}f). In contrast to shControl injected mice, the mice injected with shGEP exhibited greatly reduced mean tumor size (*P* \< 0.05) and mean tumor weight (*P* \< 0.01) in xenograft model (Fig. [3](#Fig3){ref-type="fig"}f).

GEP knockdown results in G1 arrest and increased apoptosis in CRC {#Sec19}
-----------------------------------------------------------------

Since a growth inhibitory effect was involved in siGEP transfected cells, we further explored the molecular basis involved in siGEP-suppressed tumor cell growth. We analyzed the transfectants for cell cycle parameters and apoptosis using flow cytometry. 24 h after transfection, accumulation of G1 cells increased in siGEP transfectant compared with siControls (57.8% vs. 44.8% in DLD-1; 52.6% vs. 36.2% in HCT 116 cells), while S-phase cell percentage decreased after siGEP transfection (11.6% vs. 16.8% in DLD-1; 23.8% vs. 27.3% in HCT 116 cells) in these 2 cell lines (Fig. [4](#Fig4){ref-type="fig"}a). For apoptosis analysis, the percentage of early apoptotic cells in siGEP treated cells was significantly increased compared to the siControl cells in both DLD-1 (0.8% ± 0.1% vs. 4.2% ± 0.2%, *P* \< 0.01, Fig. [4](#Fig4){ref-type="fig"}b) and HCT 116 cells (0.8% ± 0.1% vs. 5.5% ± 0.2%, *P* \< 0.01, Fig. [4](#Fig4){ref-type="fig"}b).Fig. 4GEP knockdown results in G1 arrest and apoptosis in CRC. **a** Accumulation of G1 cells increased and S-phase cell percentage decreased in siGEP transfectants compared with siControls in DLD-1cell and HCT 116 cells lines. **b** The percentage of early apoptotic cells in siGEP treated cells was significantly increased compared to the siControl cells in these two cell lines. **c** Western blot of CyclinD1, activation of cleaved Caspase 3, activation of cleaved Caspase 8 and cleaved PARP expression after silencing GEP in DLD-1 and HCT 116 cells. **d** Relative luciferase reporter activity of cell cycle signaling shown in GEP suppressed DLD-1 and HCT 116 cells. **e** RNA expression of GEP was positively associated with CyclinD1 in TCGA database. (\**P* \< 0.05; \*\**P* \< 0.01)

As proliferation-inhibition phenotypes were observed in siGEP groups, the associated cell cycle regulators and apoptosis markers were analyzed by western blot. Cyclin D1 was decreased in GEP knockdown cells, supporting the G0/G1-phase cell cycle arrest (Fig. [4](#Fig4){ref-type="fig"}c). Activation of cleaved Caspase 3, 8 and cleaved PARP were observed after silencing GEP expression (Fig. [4](#Fig4){ref-type="fig"}c), indicating that GEP inhibited apoptosis via a caspase-dependent pathway. Furthermore, luciferase reporter activity also showed GEP knockdown significantly suppressed cell cycle pathway in DLD-1and HCT 116 cells (Fig. [4](#Fig4){ref-type="fig"}d), confirming the flow cytometry and western blot result for cell cycle analysis. Besides, GEP expression was positively associated with CyclinD1 expression from RNA level in TCGA database (Fig. [4](#Fig4){ref-type="fig"}e).

GEP promotes carcinogenesis via MAPK/ERK pathway in CRCs {#Sec20}
--------------------------------------------------------

To further gain insights into the downstream signaling pathways modulated by GEP in CRC tumorigenesis, we examined the functional effect of GEP in several important cancer pathways including p53, TGFβ, Myc, Hypoxia, MAPK/ERK, NF-κB and Wnt by luciferase reporter activity assay. GEP knockdown significantly suppressed MAPK/ERK luciferase reporter activity in DLD-1 and HCT 116 cells (Fig. [5](#Fig5){ref-type="fig"}a). Western blot results showed significant suppression of phosphop-MAPK/ERK was observed in the siGEP treated CRC tumors (Fig. [5](#Fig5){ref-type="fig"}b), indicating that the MAPK/ERK signaling pathway was essential for anti-GEP-mediated growth inhibition in CRC cells. GEP led to MAPK/ERK phosphorylation and translocate into the nucleus, which stimulated cell proliferation, cell survival and metastasis of CRC (Fig. [5](#Fig5){ref-type="fig"}c).Fig. 5GEP promotes carcinogenesis via MAPK/ERK pathway in CRC. **a** A serial of promoter-luciferase assays (p53, TGFβ, Cell cycle, Myc, Hypoxia, MAPK/ERK, NF-κB and Wnt) were performed to screen for GEP target signaling pathways in DLD-1 and HCT 116 cells with GEP knockdown cells. **b** Western blot showed significant suppression of phospho-MAPK/ERK in the siGEP-treated CRC tumors cells compared with control. **c** GEP was shown to upregulate the phosphorylation of MAPK/ERK, nucleus translocation and stimulate cell proliferation, cell survival and metastasis of CRC. (\**P* \< 0.05; \*\**P* \< 0.01)

Discussion {#Sec21}
==========

In this study, we characterized clinicopathological features of GEP expression and delineated its oncogenic function in colorectal carcinogenesis.

GEP was overexpressed in CRC cell lines and patients' tumor samples. Overexpression of GEP in CRC was associated with nodal and distant metastasis and poorer clinical outcome. These findings concurred with previous observations showing GEP overexpression in different human cancers including gliomas, renal, prostatic and hepatocellular carcinomas \[[@CR25]--[@CR28]\], and the correlation with poor survival \[[@CR29]\]. Moreover, GEP expression was also positively associated with the MSI/CIMP subtypes of CRC in the TCGA cohort and patients with this kind of subtype had a very poor survival rate after relapse \[[@CR30], [@CR31]\] (Additional file [5](#MOESM5){ref-type="media"}). More importantly, increased DNA copy number of GEP could be detected in tumor samples in TCGA and Kurashina colon statistics from ONCOMINE (Additional file [6](#MOESM6){ref-type="media"}), indicating a strong possibility that overexpression of GEP was caused by copy number change from DNA level.

We further investigated the underlying mechanism of upregulating GEP on CRC. A series of in vitro and in vivo experiments confirmed GEP as an oncogenic factor in CRC. Notably, a decreased GEP level by RNA interference decreased the cell proliferation rate by MTT and colony-forming ability in the anchorage-dependent environment and decelerating xenograft formation in nude mice by disturbing cell cycle and apoptosis process and targeting the MAPK/ERK pathway. Thus, GEP played a crucial role in carcinogenesis of CRC. GEP expression has been reported in other aggressive tumors \[[@CR26], [@CR29]\] with a promoting role in cell growth regulation \[[@CR32], [@CR33]\], wound-healing process \[[@CR34], [@CR35]\], and murine development \[[@CR36]\]. It has been previously shown that GEP binds with TNFR1/2 and diminish TNF-dependent activation of MAPK/ERK by altering the TNF/TNFR interaction \[[@CR12]\]. Then it triggered activation of the MAPK/ERK and PI3K/AKT/PKB signaling cascades as well as focal adhesion kinase in the adhesion/motility pathway in cell lines derived from adrenal, breast, cervical, and bladder cancer cells, as well as in modified mouse embryo fibroblasts \[[@CR16], [@CR37]--[@CR39]\]. Therefore, control of CRC growth by GEP could be also mediated through these pathways. A decreased level of MAPK/ERK phosphorylated form was observed in the GEP knockdown group from our study. Here, we also provided evidence that GEP promoted cell migration and invasion in CRC cells in vitro. A clinical association evaluation showed that overexpression of GEP was associated significantly with advanced AJCC stage, suggesting that overexpression of GEP in CRC may facilitate an invasive and metastatic phenotype.

GEP enhanced tumor cell survival, which was partly attributable to its anti-apoptotic ability. Defective apoptosis is one of the major causative factors in tumorigenesis and caspase activation has been considered a hallmark of apoptosis \[[@CR40]\]. In this study, we demonstrated that knockdown of GEP induced cell apoptosis with caspase activation, suggesting that GEP modulated cell apoptosis via a caspase-dependent pathway. On the other hand, p53 was well-documented to play an important role in inducing cell apoptosis \[[@CR41]\], and the inhibition of p53 may contribute to the anti-apoptotic effect of GEP. We found that GEP also exhibited the effect of apoptosis both in p53 wild type and mutated CRC cells, indicating that GEP promoted tumorigenesis regardless of p53 mutation status. In keeping with this, the p53 pathway was not significantly affected when GEP knockdown by luciferase reporter activity assay for p53 pathway analysis. Thus, GEP knockdown activated cell apoptosis in a p53 independent manner.

Conclusions {#Sec22}
===========

Collectively, our findings demonstrated the oncogenic role of GEP in promoting tumorigenesis and metastasis in CRC. These findings suggest that GEP is a crucial factor in carcinogenesis of colon and rectum, and that GEP has the potential to serve as a prognostic marker and therapeutic target for CRC.
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**Additional file 1.** SuperArray SureSilencing shRNA plasmids mediated GEP knockdown. **Additional file 2.** Clinicopathological factors predicted prognosis for 190 CRC patients. **Additional file 3.** Univariable and multivariable Cox regression of prognostic parameters for disease free survival in 190 patients with colorectal cancer. **Additional file 4.** Univariable and multivariable Cox regression of prognostic parameters for overall survival in 190 patients with colorectal cancer. **Additional file 5.** GEP mRNA expression was higher in MSI/CIMP subtype than other subtypes in TCGA cohort. (\**P* \< 0.05). **Additional file 6.** Copy number change of GEP in ONCOMINE colon tissue datasets. (\**P* \< 0.05;*P* \< 0.01).
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